Neoral

(Cyclosporine)

ApprovedSmall molecule

Cyclosporine is used to prevent the body's immune system from rejecting transplanted organs like kidneys, heart, or liver, and also to treat severe autoimmune conditions like rheumatoid arthritis and certain eye diseases by suppressing overactive immune responses.[2] Neoral is currently approved and in use across 129 indications[4].[1]

Neoral is one of 2183 small molecule programs targeting Glioma. It is currently in Approved.

129

Indications

405

Total Trials

Active Trials

2,182

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

HIV InfectionApproved

Renal Artery StenosisApproved

Bronchiolitis ObliteransApproved

MetastasisApproved

Cardiac ArrestApproved

Ischemia Reperfusion InjuryApproved

Corneal DiseaseActive, not recruiting

Systemic Inflammatory Response SyndromeApproved

Venous ThromboembolismApproved

GliomaPhase 1

Active, not recruiting

HIV InfectionApproved

Approved

Renal Artery StenosisApproved

Approved

Bronchiolitis ObliteransApproved

Approved

MetastasisApproved

Approved

Cardiac ArrestApproved

Approved

Ischemia Reperfusion InjuryApproved

Approved

Corneal DiseaseApproved

Active, not recruiting

Systemic Inflammatory Response SyndromeApproved

Approved

Venous ThromboembolismApproved

Approved

Showing 10 of 129 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

8 2

Halaven

Eisai

Preclinical

38 3

Trodelvy

Gilead

Preclinical

37 4

Avastin

Voltaren

1 6

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 7

Spravato

WWim Janssens

Preclinical

2 8

Nubain

AAultman Health Foundation

Preclinical

1 9

Tricor

JJagotec

Preclinical

1 10

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Hemolytic Anemia

NCT05057468

Q2 2027

Phase 2Active, not recruiting

Membranous Nephropathy

NCT06642909

Q3 2027

Phase 2Not yet recruiting

Neuroblastoma

NCT05303727

Q2 2028

Post-ApprovalNot yet recruiting

Efficacy and Safety

NCT06364319

Clinical

Trials by Indication[1]

Kidney Transplant13 trials

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

Completed· Pfizer logo

Pfizer·Phase 2·NCT00483756·338 enrolled

Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus

Completed· Pfizer logo

Pfizer·Phase 4·NCT00195468·280 enrolled

Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00790439

Show 10 more trials

Everolimus in de Novo Kidney Transplant Recipients

Completed· Novartis logo

Novartis·Phase 3·NCT01410448·383 enrolled

A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01820572·446 enrolled

Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients

Withdrawn· Pfizer logo

Pfizer·Phase 2·NCT00556257

Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus

Completed· Pfizer logo

Pfizer·Phase 4·NCT00507793·385 enrolled

OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

Completed· Roche logo

Roche·Phase 3·NCT02005562·252 enrolled

Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients

Completed· Pfizer logo

Pfizer·Phase 3·NCT00428064·408 enrolled

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Completed· Pfizer logo

Pfizer·Phase 2·NCT00658359·178 enrolled

Study Evaluating Sirolimus in Kidney Transplant Recipients.

Completed· Pfizer logo

Pfizer·Phase 3·NCT00167947·150 enrolled

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

Terminated·—·Phase 3·NCT00005113·102 enrolled

Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00007787·350 enrolled

Stem Cell Transplant12 trials

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting·—·Phase 2·NCT00544115·260 enrolled

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00075478·87 enrolled

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers

Completed·UUniversity of California, Davis·Phase 2·NCT00619645·8 enrolled

Show 9 more trials

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00096161·36 enrolled

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00027560·51 enrolled

Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00378534·116 enrolled

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00051311·62 enrolled

Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00005941

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Withdrawn·UUniversity of Nebraska·Phase 1/2·NCT00816413

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT01300572·16 enrolled

Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00317785·50 enrolled

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

Unknown status·IInstitut Paoli-Calmettes·Phase 2·NCT00740467·50 enrolled

Interaction9 trials

Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus

Completed·TThomas Jefferson University·Phase 1·NCT03083782·12 enrolled

Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT02281370·39 enrolled

Drug Interaction Study of Isavuconazole and Cyclosporine

Completed· Astellas logo

Astellas·Phase 1·NCT01494597·24 enrolled

Show 6 more trials

Drug-Drug Interaction Study Between Colchicine and Cyclosporine

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00983931·24 enrolled

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05202145·61 enrolled

A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01514968·18 enrolled

Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04149678·40 enrolled

Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study

Completed· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 1·NCT06892756·30 enrolled

Drug-Drug Interaction Study in Healthy Adult Volunteers

Completed·KKowa Research Institute, Inc.·Phase 1·NCT02276001·20 enrolled

Lymphoma7 trials

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Terminated·SStanford University·Phase 2·NCT00481832·50 enrolled

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00119392·42 enrolled

Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00041288·10 enrolled

Show 4 more trials

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Unknown status·JJoseph Tuscano·Phase 2·NCT01811368·20 enrolled

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00908180·47 enrolled

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00002759·3 enrolled

Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma

Completed·—·Phase 3·NCT00928018·139 enrolled

Hematologic Cancer6 trials

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00723099·73 enrolled

Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00031980·30 enrolled

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

Terminated·UUniversity of Rochester·N/A·NCT00255684·16 enrolled

Show 3 more trials

Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT00290641·68 enrolled

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT00290628·43 enrolled

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

Completed·—·Phase 2·NCT00003335·44 enrolled

86 more indications

Severe Aplastic Anemia6 trials

Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT00354419·30 enrolled

Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia

Completed·BBing Han·Phase 2·NCT05399732·58 enrolled

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT04304820·80 enrolled

Show 3 more trials

Completed·MMichael Pulsipher·N/A·NCT02845596·40 enrolled

Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

Unknown status·FFederico II University·Phase 2·NCT00895739·50 enrolled

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00343785·21 enrolled

Kidney Cancer6 trials

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

Completed·UUNICANCER·Phase 2·NCT00056095·57 enrolled

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00005851·11 enrolled

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00078858·37 enrolled

Show 3 more trials

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Completed·FFred Hutchinson Cancer Center·N/A·NCT00005799·55 enrolled

Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00243009·1 enrolled

Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT00006968·4 enrolled

Acute Lymphoblastic Leukemia6 trials

Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00027547

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00988715·17 enrolled

Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00022126·6 enrolled

Show 3 more trials

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00036738·28 enrolled

Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Unknown status·JJonsson Comprehensive Cancer Center·N/A·NCT00093587

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00022737·220 enrolled

Leukemia5 trials

Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT01041508·18 enrolled

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

Terminated·BBaxalta now part of Shire·Phase 3·NCT00003056·105 enrolled

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Completed·RRobert Lowsky·Phase 2·NCT02424968·18 enrolled

Show 2 more trials

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00357565·34 enrolled

Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00363779·5 enrolled

Bone Marrow Transplantation5 trials

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002547·280 enrolled

Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004323·10 enrolled

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005852

Show 2 more trials

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

Terminated·LLouisiana State University Health Sciences Center Shreveport·Phase 1·NCT00003060·6 enrolled

Bone Marrow Transplantation in Treating Children With Sickle Cell Disease

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00004485·50 enrolled

Acute Myeloid Leukemia5 trials

S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00053014·5 enrolled

Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00045435·17 enrolled

Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01252667·44 enrolled

Show 2 more trials

Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Completed·—·Phase 2·NCT01020734·263 enrolled

Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00089050

Chronic Myelogenous Leukemia4 trials

Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00002832·14 enrolled

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00027924

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01426334·4 enrolled

Show 1 more trial

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00110058·40 enrolled

Myeloproliferative Disorder4 trials

Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00002792·20 enrolled

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Completed·EEverett Meyer·Phase 2·NCT01392989·44 enrolled

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00397813·77 enrolled

Show 1 more trial

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00054340

Breast Cancer4 trials

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

Terminated·UUniversity of California, San Diego·Phase 2·NCT00074269·5 enrolled

Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00365287·148 enrolled

Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01105650·13 enrolled

Show 1 more trial

Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

Unknown status·UUniversity of California, Davis·Phase 1·NCT00003920·18 enrolled

Liver Transplant3 trials

Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

Completed· Roche logo

Roche·Phase 4·NCT00118742·293 enrolled

Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids

Terminated· Roche logo

Roche·Phase 2·NCT02630563·9 enrolled

A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients

Completed· Novartis logo

Novartis·Phase 4·NCT00332462·34 enrolled

Multiple Myeloma3 trials

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00003954·40 enrolled

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00793572·32 enrolled

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006184·20 enrolled

Chronic Lymphocytic Leukemia3 trials

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Completed·GGerman CLL Study Group·Phase 1/2·NCT00281983·100 enrolled

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00104858·66 enrolled

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00425802·61 enrolled

Fanconi Anemia3 trials

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00453388·6 enrolled

Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00630253·31 enrolled

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00093743·2 enrolled

Prevention3 trials

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Completed·SStanford University·Phase 2·NCT00186628·36 enrolled

Aerosol Cyclosporine for Prevention of Lung Rejection

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00268515

Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease

Unknown status·RRabin Medical Center·Phase 2·NCT02478424·10 enrolled

Tacrolimus3 trials

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT01038167·20 enrolled

Diabetogenicity of Cyclosporine and Tacrolimus

Completed·UUniversity of Aarhus·Phase 4·NCT00766909·18 enrolled

A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 1·NCT01479881·29 enrolled

Adult2 trials

A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.

Completed· Pfizer logo

Pfizer·Phase 1·NCT06541678·16 enrolled

A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT06837259·26 enrolled

Membranous Nephropathy2 trials

A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy

Active, not recruiting·BBioRay Pharmaceutical Co., Ltd.·Phase 2·NCT06642909·135 enrolled

MEmbranous Nephropathy Trial Of Rituximab

Completed·MMayo Clinic·Phase 2/3·NCT01180036·130 enrolled

Myelodysplastic Syndrome2 trials

Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00806598·53 enrolled

S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 3·NCT00005866·240 enrolled

Transplantation2 trials

Allogeneic Transplantation From Related Haploidentical Donors

Completed·SStanford University·Phase 2·NCT00185692·16 enrolled

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Completed·SStanford University·Phase 2·NCT00899847·9 enrolled

Stem Cell Transplantation2 trials

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00520130·92 enrolled

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·NNorthwestern University·Phase 1·NCT00004232

Aplastic Anemia2 trials

Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia

Unknown status·OOffice of Rare Diseases (ORD)·Phase 1/2·NCT00319878·52 enrolled

Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00005935·130 enrolled

Chronic Hepatitis2 trials

Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection

Completed·—·Phase 4·NCT00163657·312 enrolled

A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01938625·35 enrolled

COVID-192 trials

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active, not recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT04488081·1,500 enrolled

Cyclosporine For The Treatment Of COVID-19(+)

Completed·—·Phase 2·NCT04492891·47 enrolled

Acute Leukemia2 trials

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00002831·24 enrolled

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Unknown status·DDutch Childhood Oncology Group·N/A·NCT00550992·445 enrolled

Hematologic Malignancies2 trials

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

Completed·SStanford University·Phase 2·NCT00185640·303 enrolled

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

Completed·NNohla Therapeutics, Inc.·Phase 2·NCT01175785·15 enrolled

Graft Versus Host Disease2 trials

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Withdrawn·MMesoblast International Sàrl·Phase 2·NCT00081055

Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease

Completed·SSeoul National University Hospital·Phase 2/3·NCT01788501·50 enrolled

Treatment2 trials

Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN

Terminated·PPeking Union Medical College Hospital·Phase 3·NCT04743739·12 enrolled

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment

Completed·PPeking University Third Hospital·Phase 4·NCT05294666·89 enrolled

Myelodysplastic Syndromes2 trials

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00008177·79 enrolled

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00045305·17 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects

Completed·AAmsterdam Molecular Therapeutics·Phase 2/3·NCT00891306·5 enrolled

Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD

Not yet recruiting·PPeking University People's Hospital·Phase 4·NCT06364319·118 enrolled

Peripheral Blood Stem Cell Transplantation2 trials

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01427881·43 enrolled

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT03602898

Anemia2 trials

Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00317876·25 enrolled

Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia

Completed·UUniversity of Minnesota·Phase 1/2·NCT00005898·30 enrolled

Renal Transplant Recipients2 trials

Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function

Unknown status·UUniversity Hospital Birmingham·Phase 4·NCT00541814·90 enrolled

Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients

Completed· Roche logo

Roche·Phase 3·NCT02686619·237 enrolled

Bone Marrow Transplant2 trials

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

Terminated·OOHSU Knight Cancer Institute·N/A·NCT00253552·4 enrolled

Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer

Active, not recruiting·—·Phase 2·NCT00534430·30 enrolled

Melanoma1 trial

Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00006233

Kidney1 trial

Shift to Everolimus (RAD) Kidney Sparing Study

Terminated·UUniversity of Bologna·Phase 4·NCT00420537·34 enrolled

Myocarditis1 trial

Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

Completed·MMayo Clinic·Phase 2·NCT00004482·40 enrolled

Sickle Cell Disease1 trial

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Completed·MMonica Bhatia·Phase 1·NCT02867800·24 enrolled

Hematologic Disorder1 trial

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders

Completed·—·Phase 2·NCT00636909·25 enrolled

Immune System1 trial

A Study to Test the Effect of Cyclosporine on the Immune System of Patients With Early HIV Disease

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000880·30 enrolled

Thrombotic Thrombocytopenic Purpura1 trial

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

Completed·OOhio State University·Phase 3·NCT00713193·26 enrolled

Interstitial Cystitis1 trial

Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action

Completed·TThe Cleveland Clinic·Phase 2·NCT01990898·26 enrolled

Renal Transplantation1 trial

Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation

Unknown status·UUniversity Hospital, Antwerp·Phase 4·NCT00903188·152 enrolled

Metabolic Disease1 trial

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003662·90 enrolled

Ulcerative Colitis1 trial

Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis

Not yet recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT05112263·96 enrolled

Colorectal Cancer1 trial

Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00003950·16 enrolled

Metastatic Colorectal Cancer1 trial

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02188264·40 enrolled

ESS1 trial

Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01504906·20 enrolled

Prospective1 trial

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00784719·327 enrolled

Genetic Disorder1 trial

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008307·52 enrolled

Severe Combined Immunodeficiency1 trial

Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00008450·6 enrolled

Retinoblastoma1 trial

Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma

Active, not recruiting·TThe Hospital for Sick Children·Phase 2·NCT00110110·71 enrolled

Myocardial Protection1 trial

Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery

Terminated·TThe University of Texas Health Science Center, Houston·Phase 1·NCT00990795·72 enrolled

Safety and Efficacy1 trial

Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]

Unknown status·AAmsterdam Molecular Therapeutics·Phase 2/3·NCT01109498·14 enrolled

Prophylaxis1 trial

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting·UUniversity Hospital, Angers·Phase 2/3·NCT02416388·3,100 enrolled

Mycosis Fungoides1 trial

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT00047060·5 enrolled

Islet Transplantation1 trial

Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation

Completed·UUniversity of Minnesota·Phase 1/2·NCT00286624·6 enrolled

Inflammatory Response1 trial

Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye

Unknown status·ZZhongshan Ophthalmic Center, Sun Yat-sen University·N/A·NCT05131152·100 enrolled

Hemoglobinopathies1 trial

HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity

Completed·NNorthwell Health·Phase 1/2·NCT02435901·29 enrolled

Allograft1 trial

Optima: Optimizing Prograf Therapy in Maintenance Allografts II

Completed·—·Phase 4·NCT00905515·63 enrolled

Anaplastic Large Cell Lymphoma1 trial

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Unknown status·EEuropean Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma·N/A·NCT00317408·96 enrolled

Cardiac Transplant1 trial

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Completed· Roche logo

Roche·Phase 4·NCT00048165·434 enrolled

Myelodysplasia1 trial

Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia

Completed·—·Phase 2·NCT00005937·42 enrolled

Histiocytosis1 trial

Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00334672·288 enrolled

Immunosuppression1 trial

Phase I/II Thymus Transplantation With Immunosuppression #950

Completed·SSumitomo Pharma Switzerland GmbH·Phase 1/2·NCT00579527·14 enrolled

Tic Disorder1 trial

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Unknown status·—·N/A·NCT00006056·40 enrolled

Hemolytic Anemia1 trial

Second-line Treatment of Primary Autoimmune Hemolytic Anemia

Recruiting·—·Phase 3·NCT05057468·30 enrolled

Angioimmunoblastic T-Cell Lymphoma1 trial

Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

Terminated·EEastern Cooperative Oncology Group·Phase 2·NCT00070291·4 enrolled

Experimental1 trial

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03419910·54 enrolled

Neuroblastoma1 trial

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05303727·64 enrolled

Cancer1 trial

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00796068·130 enrolled

Effectiveness1 trial

Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital

Completed·—·Phase 3·NCT04979884·66 enrolled

Hospitalized Patients1 trial

Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19

Completed·IInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz·Phase 4·NCT04392531·111 enrolled

Advanced1 trial

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00719849·13 enrolled

Psoriasis Vulgaris1 trial

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

Completed·RRockefeller University·Phase 1/2·NCT00050648·20 enrolled

Chronic Graft Versus Host Disease1 trial

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

Completed·CChildren's Oncology Group·Phase 3·NCT00031824·82 enrolled

Surgical1 trial

Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy Procedure

Completed·MMashhad University of Medical Sciences·Phase 2·NCT02114073·40 enrolled

Dry Eye Syndrome1 trial

Tear Film Markers in Dry Eye Syndrome

Withdrawn·VVishal Jhanji·Phase 4·NCT04515329

Refractory Solid Tumors1 trial

Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors

Completed·MMilton S. Hershey Medical Center·Phase 1·NCT00112645·10 enrolled

Hematological Malignancies1 trial

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00040846·60 enrolled

Atopic Dermatitis1 trial

Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis

Completed·MMedical University of Silesia·N/A·NCT06509243·132 enrolled

Allogeneic Stem Cell Transplantation1 trial

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00080925·20 enrolled

Myeloid Leukemia1 trial

Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00002789·100 enrolled

Hematologic Disease1 trial

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00376519·3 enrolled

Drug Interactions1 trial

Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02016625·32 enrolled

Immunosuppressive Agents1 trial

Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients

Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT03150134·100 enrolled

Unspecified2 trials

Intra-Osseous Co-Transplant of UCB and hMSC

Completed·—·Phase 1·NCT02181478·6 enrolled

A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).

Completed· Roche logo

Roche·Phase 2·NCT01292226·45 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 14, 1983

SANDIMMUNE

NDA NDA050574

Nov 14, 1983

SANDIMMUNE

NDA NDA050573

Mar 2, 1990

SANDIMMUNE

NDA NDA050625

Jul 14, 1995

NEORAL

NDA NDA050716

Jul 14, 1995

NEORAL

NDA NDA050715

Dec 23, 2002

RESTASIS

NDA NDA050790

Aug 14, 2018

CEQUA

NDA NDA210913

Jun 23, 2021

VERKAZIA

NDA NDA214965

May 30, 2023

VEVYE

NDA NDA217469

Sources

References

[1]
ClinicalTrials.gov — 405 trial records for Cyclosporine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Neoral drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Cyclosporine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Cyclosporine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA217469). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Neoral. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cyclophilin a Modulator[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Novartis

Patent Landscape[6]

Patent Cliff

Nov 3, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8524779Jan 27, 2026

7973081Jan 27, 2026

9956289Jan 27, 2026

11612658Jan 27, 2026

9220694Jan 27, 2026

17 more patents

8298568Nov 3, 2027

9132071Jun 2, 2029

8614178Dec 13, 2030

8292129Feb 25, 2031

8561859Apr 16, 2032

10441630Aug 23, 2033

8980839Aug 23, 2033

9937225Aug 23, 2033

9676525Feb 7, 2034

9669974May 11, 2034

12496326Sep 29, 2036

11951153Feb 28, 2037

10918694Feb 28, 2037

10813976Sep 22, 2037

11154513Nov 20, 2038

11413323Oct 11, 2039

12059449Apr 1, 2042